| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 50mg |
|
||
| Other Sizes |
| Targets |
LASV inhibitor 3.3 targets lysosome-associated membrane protein 1 (LAMP1), a host factor that binds to the LASV glycoprotein (GP) during infection. LAMP1 is a cellular receptor that facilitates viral entry and membrane fusion. By targeting LAMP1, LASV inhibitor 3.3 blocks LASV GP-mediated entry and infection. This host-targeting approach provides a strategy for inhibiting Lassa fever virus and potentially other arenaviruses.
|
|---|---|
| ln Vitro |
At an IC50 value of 1.8 μM, LASV inhibitor 3.3 (1 nM-100 μM; 1 h) inhibits the transduction of the specific viral glycoprotein pseudotype by the murine leukemia virus (MLV) [1]. The binding of LAMP1 to LASV GP is inhibited by LASV inhibitor 3.3 (1 and 10 μM; 1 h) [1].
In vitro, LASV inhibitor 3.3 inhibits LASV GP-mediated infection and cross-links to the LASV receptor, LAMP1, in cells. It selectively blocks Lassa virus glycoprotein-mediated entry. These in vitro activities support its use in studying arenavirus biology, host-virus interactions, and viral entry mechanisms. LASV inhibitor 3.3 serves as a reference inhibitor for high-throughput arenavirus entry assays. |
| ln Vivo |
In vivo data for LASV inhibitor 3.3 is not extensively reported in publicly available sources. As a specific inhibitor of LASV entry, the compound has potential applications in animal models of Lassa fever virus infection. By blocking viral entry, LASV inhibitor 3.3 could prevent or treat Lassa fever. However, specific published in vivo efficacy studies are not detailed in the current literature. LASV inhibitor 3.3 is primarily used as a research tool for studying arenavirus entry and host-virus interactions.
|
| Enzyme Assay |
The in vitro LASV entry inhibition assay for LASV inhibitor 3.3 uses cells infected with LASV or pseudotyped viruses expressing LASV glycoprotein. Cells are treated with varying concentrations of the compound, and viral entry is measured by quantifying reporter gene expression or viral replication. The compound's ability to cross-link to LAMP1 is confirmed by co-immunoprecipitation or proximity ligation assays. IC50 values are calculated from dose-response curves.
|
| Cell Assay |
Western Blot Analysis[1]
Cell Types: 293T LAMP1 KO cells expressing LASV GP-His and 293T pX459 cells Tested Concentrations: 1 and 10 μM Incubation Duration: 1 hour Experimental Results: Inhibited the LASV GP binds to LAMP1. Cellular assays for LASV inhibitor 3.3 are conducted in LASV-susceptible cell lines. Cells are treated with varying concentrations of LASV inhibitor 3.3 and infected with LASV or pseudotyped viruses. Viral entry is measured by quantifying reporter gene expression or viral RNA levels. Cell viability is assessed to confirm that inhibition is not due to cytotoxicity. The compound's effects on LAMP1-GP interaction are evaluated by co-immunoprecipitation or immunofluorescence. |
| Animal Protocol |
In vivo studies for LASV inhibitor 3.3 would typically involve animal models of Lassa fever, such as guinea pigs or non-human primates. The compound would be administered via intraperitoneal or oral routes at doses determined by pharmacokinetic studies. Efficacy would be assessed by measuring viral loads, clinical signs of infection, and survival rates. However, specific published in vivo protocols for LASV inhibitor 3.3 are not available in the current literature. The compound is currently used as a research tool.
|
| ADME/Pharmacokinetics |
Pharmacokinetic data for LASV inhibitor 3.3 is not extensively reported in publicly available sources. The compound has a molecular weight of 471.63 g/mol and a molecular formula of C30H37N3O2. It has a CAS number of 554438-52-7. It is soluble in DMSO. Storage: store at -20°C in a dry, light-protected environment. As a small molecule, it is expected to have moderate bioavailability. Detailed PK parameters such as half-life are not available.
|
| Toxicity/Toxicokinetics |
Toxicity data for LASV inhibitor 3.3 is limited in publicly available sources. As with all research compounds, LASV inhibitor 3.3 is intended for research use only and not for human therapeutic applications. Standard in vitro cytotoxicity assays and in vivo tolerability studies would be required for a complete toxicity assessment. Resistance may occur through mutations in the polymerase domain.
|
| References | |
| Additional Infomation |
LASV inhibitor 3.3 (CAS 554438-52-7) is a specific inhibitor of Lassa fever virus that targets LAMP1, a host factor that binds to the LASV glycoprotein during infection. It inhibits LASV GP-mediated entry and cross-links to LAMP1 in cells. It has a molecular formula of C30H37N3O2 and a molecular weight of 471.63 g/mol. LASV inhibitor 3.3 is a valuable research tool for studying arenavirus entry and host-virus interactions.
|
| Molecular Formula |
C30H37N3O2
|
|---|---|
| Molecular Weight |
471.633687734604
|
| Exact Mass |
471.288
|
| CAS # |
554438-52-7
|
| PubChem CID |
5082945
|
| Appearance |
White to off-white solid powder
|
| LogP |
4.7
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
6
|
| Heavy Atom Count |
35
|
| Complexity |
702
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
O=C(C12CC3CC(CC(C3)C1)C2)NCC(N1CCN(C(C2C=CC=CC=2)C2C=CC=CC=2)CC1)=O
|
| InChi Key |
CUSOKWBOIRFXDP-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C30H37N3O2/c34-27(21-31-29(35)30-18-22-15-23(19-30)17-24(16-22)20-30)32-11-13-33(14-12-32)28(25-7-3-1-4-8-25)26-9-5-2-6-10-26/h1-10,22-24,28H,11-21H2,(H,31,35)
|
| Chemical Name |
N-[2-(4-benzhydrylpiperazin-1-yl)-2-oxoethyl]adamantane-1-carboxamide
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : 25 mg/mL (53.01 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.1203 mL | 10.6015 mL | 21.2031 mL | |
| 5 mM | 0.4241 mL | 2.1203 mL | 4.2406 mL | |
| 10 mM | 0.2120 mL | 1.0602 mL | 2.1203 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
